Status:
UNKNOWN
Prediction of Bleeding Risk After Anticoagulant Therapy for Atrial Fibrillation Based on Proteomics and Metabolomics
Lead Sponsor:
Yue LI
Conditions:
Atrial Fibrillation
Bleeding
Eligibility:
All Genders
18+ years
Brief Summary
Objectives: Atrial fibrillation (AF) is the most common arrhythmia. Anticoagulation with warfarin or new oral anticoagulants in patients with AF can significantly reduce thromboembolic events. However...
Eligibility Criteria
Inclusion
- Age 18 years or above
- Admission with atrial fibrillation or clinic visit for atrial fibrillation
- Receive routine anticoagulant therapy;
- Signing the consent form
Exclusion
- Pregnant women;
- Lactating women;
- Severe mitral stenosis;
- Severe impairment of liver function;
- Severe renal insufficiency;
- Thyroid dysfunction requiring treatment;
- Have a history of severe bleeding within five years, such as intracerebral hemorrhage and gastrointestinal bleeding.
Key Trial Info
Start Date :
December 20 2021
Trial Type :
OBSERVATIONAL
Allocation :
ESTIMATED
End Date :
December 31 2023
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT05181774
Start Date
December 20 2021
End Date
December 31 2023
Last Update
January 6 2022
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
Yan
Harbin, Heilongjiang, China, 150001